Literature DB >> 30646262

Association of Prior Vaccination With Influenza Vaccine Effectiveness in Children Receiving Live Attenuated or Inactivated Vaccine.

Huong Q McLean1, Herve Caspard2, Marie R Griffin3, Manjusha Gaglani4, Timothy R Peters5, Katherine A Poehling5, Christopher S Ambrose2, Edward A Belongia1.   

Abstract

Importance: Some studies have reported negative effects of prior-season influenza vaccination. Prior-season influenza vaccination effects on vaccine effectiveness (VE) in children are not well understood. Objective: To assess the association of prior-season influenza vaccination with subsequent VE in children aged 2 to 17 years. Design, Setting, and Participants: This multiseason, test-negative case-control study was conducted in outpatient clinics at 4 US sites among children aged 2 to 17 years with a medically attended febrile acute respiratory illness. Participants were recruited during the 2013-2014, 2014-2015, and 2015-2016 seasons when influenza circulated locally. Cases were children with influenza confirmed by reverse-transcription polymerase chain reaction. Test-negative control individuals were children with negative test results for influenza. Exposures: Vaccination history, including influenza vaccine type received in the enrollment season (live attenuated influenza vaccine [LAIV], inactivated influenza vaccine [IIV], or no vaccine) and season before enrollment (LAIV, IIV, or no vaccine), determined from medical records and immunization registries. Main Outcomes and Measures: LAIV and IIV effectiveness by influenza type and subtype (influenza A[H1N1]pdm09, influenza A[H3N2], or influenza B), estimated as 100 × (1 - odds ratio) in a logistic regression model with adjustment for potential confounders. Prior season vaccination associations were assessed with an interaction term.
Results: Of 3369 children (1749 [52%] male; median age, 6.6 years [range, 2-17 years]) included in the analysis, 772 (23%) had a positive test result for influenza and 1674 (50%) were vaccinated in the enrollment season. Among LAIV recipients, VE against influenza A(H3N2) was higher among children vaccinated in both the enrollment and 1 prior season (50.3% [95% CI, 17.0% to 70.2%]) than among those without 1 prior season vaccination (-82.4% [95% CI, -267.5% to 9.5%], interaction P < .001). The effectiveness of LAIV against influenza A(H1N1)pdm09 was not associated with prior season vaccination among those with prior season vaccination (47.5% [95% CI, 11.4% to 68.9%]) and among those without prior season vaccination (7.8% [95% CI, -101.9% to 57.9%]) (interaction P = .37). Prior season vaccination was not associated with effectiveness of IIV against influenza A(H3N2) (38.7% [95% CI, 6.8% to 59.6%] among those with prior-season vaccination and 23.2% [95% CI, -38.3% to 57.4%] among those without prior-season vaccination, interaction P = .16) or with effectiveness of IIV against influenza A[H1N1]pdm09 (72.4% [95% CI, 56.0% to 82.7%] among those with prior season vaccination and 67.5% [95% CI, 32.1% to 84.4%] among those without prior season vaccination, interaction P = .93). Residual protection from prior season vaccination only (no vaccination in the enrollment season) was observed for influenza B (LAIV: 60.0% [95% CI, 36.8% to 74.7%]; IIV: 60.0% [36.9% to 74.6%]). Similar results were observed in analyses that included repeated vaccination in 2 and 3 prior seasons. Conclusions and Relevance: Influenza VE varied by influenza type and subtype and vaccine type, but prior-season vaccination was not associated with reduced VE. These findings support current recommendations for annual influenza vaccination of children.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30646262      PMCID: PMC6324442          DOI: 10.1001/jamanetworkopen.2018.3742

Source DB:  PubMed          Journal:  JAMA Netw Open        ISSN: 2574-3805


  48 in total

Review 1.  A systematic review of the efficacy of live attenuated influenza vaccine upon revaccination of children.

Authors:  Herve Caspard; Terho Heikkinen; Robert B Belshe; Christopher S Ambrose
Journal:  Hum Vaccin Immunother       Date:  2016-07-02       Impact factor: 3.452

2.  Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines.

Authors:  Xiao-Song He; Tyson H Holmes; Caiqiu Zhang; Kutubuddin Mahmood; George W Kemble; David B Lewis; Cornelia L Dekker; Harry B Greenberg; Ann M Arvin
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

3.  Duration of protection provided by live attenuated influenza vaccine in children.

Authors:  Christopher S Ambrose; Tingting Yi; Robert E Walker; Edward M Connor
Journal:  Pediatr Infect Dis J       Date:  2008-08       Impact factor: 2.129

4.  Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses.

Authors:  Paula A Lanthier; Gail E Huston; Amy Moquin; Sheri M Eaton; Frank M Szaba; Lawrence W Kummer; Micheal P Tighe; Jacob E Kohlmeier; Patrick J Blair; Michael Broderick; Stephen T Smiley; Laura Haynes
Journal:  Vaccine       Date:  2011-08-02       Impact factor: 3.641

5.  Effect of Repeated Vaccination With the Same Vaccine Component Against 2009 Pandemic Influenza A(H1N1) Virus.

Authors:  Iván Martínez-Baz; Itziar Casado; Ana Navascués; Jorge Díaz-González; Aitziber Aguinaga; Laura Barrado; Josu Delfrade; Carmen Ezpeleta; Jesús Castilla
Journal:  J Infect Dis       Date:  2017-03-15       Impact factor: 5.226

Review 6.  Repeated annual influenza vaccination and vaccine effectiveness: review of evidence.

Authors:  Edward A Belongia; Danuta M Skowronski; Huong Q McLean; Catharine Chambers; Maria E Sundaram; Gaston De Serres
Journal:  Expert Rev Vaccines       Date:  2017-06-09       Impact factor: 5.217

7.  The case test-negative design for studies of the effectiveness of influenza vaccine.

Authors:  Ivo M Foppa; Michael Haber; Jill M Ferdinands; David K Shay
Journal:  Vaccine       Date:  2013-04-23       Impact factor: 3.641

8.  Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season.

Authors:  Edward A Belongia; Maria E Sundaram; David L McClure; Jennifer K Meece; Jill Ferdinands; Jeffrey J VanWormer
Journal:  Vaccine       Date:  2014-06-21       Impact factor: 3.641

9.  Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12.

Authors:  J Castilla; I Martínez-Baz; V Martínez-Artola; G Reina; F Pozo; M García Cenoz; M Guevara; J Morán; F Irisarri; M Arriazu; E Albéniz; C Ezpeleta; A Barricarte
Journal:  Euro Surveill       Date:  2013-01-31

10.  Effectiveness of pandemic and seasonal influenza vaccines in preventing laboratory-confirmed influenza in adults: a clinical cohort study during epidemic seasons 2009-2010 and 2010-2011 in Finland.

Authors:  Ritva K Syrjänen; Jukka Jokinen; Thedi Ziegler; Jonas Sundman; Mika Lahdenkari; Ilkka Julkunen; Terhi M Kilpi
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

View more
  13 in total

1.  A randomized controlled trial of antibody response to 2018-19 cell-based vs. egg-based quadrivalent inactivated influenza vaccine in children.

Authors:  Krissy K Moehling; Richard K Zimmerman; Mary Patricia Nowalk; Chyongchiou Jeng Lin; Judith M Martin; John F Alcorn; Michael Susick; Ashley Burroughs; Crystal Holiday; Brendan Flannery; Min Z Levine
Journal:  Vaccine       Date:  2020-06-21       Impact factor: 3.641

2.  The immunomodulatory effects of vitamin D drops in children with recurrent respiratory tract infections.

Authors:  Jianqiu Xiao; Wei He
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

3.  A Retrospective Test-Negative Case-Control Study to Evaluate Influenza Vaccine Effectiveness in Preventing Hospitalizations in Children.

Authors:  Inci Yildirim; Carol M Kao; Ashley Tippett; Piyarat Suntarattiwong; Mohamed Munye; Jumi Yi; Mohnd Elmontser; Elizabeth Quincer; Chris Focht; Nora Watson; Hande Bilen; Julia M Baker; Ben Lopman; Elena Hogenesch; Christina A Rostad; Evan J Anderson
Journal:  Clin Infect Dis       Date:  2021-11-16       Impact factor: 20.999

4.  Antibody-dependent cell-mediated cytotoxicity antibody responses to inactivated and live-attenuated influenza vaccination in children during 2014-15.

Authors:  Kelsey Florek; James Mutschler; Huong Q McLean; Jennifer P King; Brendan Flannery; Edward A Belongia; Thomas C Friedrich
Journal:  Vaccine       Date:  2019-11-18       Impact factor: 3.641

5.  Earliest infections predict the age distribution of seasonal influenza A cases.

Authors:  Philip Arevalo; Huong Q McLean; Edward A Belongia; Sarah Cobey
Journal:  Elife       Date:  2020-07-07       Impact factor: 8.140

Review 6.  Influenza Vaccination: Effectiveness, Indications, and Limits in the Pediatric Population.

Authors:  Chiara Mameli; Ilaria Cocchi; Mara Fumagalli; Gianvincenzo Zuccotti
Journal:  Front Pediatr       Date:  2019-07-30       Impact factor: 3.418

7.  Alteration of humoral, cellular and cytokine immune response to inactivated influenza vaccine in patients with Sickle Cell Disease.

Authors:  Carole Nagant; Cyril Barbezange; Laurence Dedeken; Tatiana Besse-Hammer; Isabelle Thomas; Bhavna Mahadeb; André Efira; Alice Ferster; Francis Corazza
Journal:  PLoS One       Date:  2019-10-10       Impact factor: 3.240

8.  Effect of Previous-Season Influenza Vaccination on Serologic Response in Children During 3 Seasons, 2013-2014 Through 2015-2016.

Authors:  Huong Q McLean; Jennifer P King; Pamela Talley; Brendan Flannery; Sarah Spencer; Min Z Levine; Thomas C Friedrich; Edward A Belongia
Journal:  J Pediatric Infect Dis Soc       Date:  2020-04-30       Impact factor: 3.164

9.  Impact of Immune Priming, Vaccination, and Infection on Influenza A(H3N2) Antibody Landscapes in Children.

Authors:  Michael Hinojosa; Samuel S Shepard; Jessie R Chung; Jennifer P King; Huong Q McLean; Brendan Flannery; Edward A Belongia; Min Z Levine
Journal:  J Infect Dis       Date:  2021-08-02       Impact factor: 5.226

10.  Impact of Pre-Existing Immunity to Influenza on Live-Attenuated Influenza Vaccine (LAIV) Immunogenicity.

Authors:  Sreeja Roy; Clare M Williams; Danushka K Wijesundara; Yoichi Furuya
Journal:  Vaccines (Basel)       Date:  2020-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.